These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 26058072)

  • 1. Antagonizing ClpP: A New Power Play in Targeted Therapy for AML.
    Larkin K; Byrd JC
    Cancer Cell; 2015 Jun; 27(6):747-9. PubMed ID: 26058072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia.
    Cole A; Wang Z; Coyaud E; Voisin V; Gronda M; Jitkova Y; Mattson R; Hurren R; Babovic S; Maclean N; Restall I; Wang X; Jeyaraju DV; Sukhai MA; Prabha S; Bashir S; Ramakrishnan A; Leung E; Qia YH; Zhang N; Combes KR; Ketela T; Lin F; Houry WA; Aman A; Al-Awar R; Zheng W; Wienholds E; Xu CJ; Dick J; Wang JC; Moffat J; Minden MD; Eaves CJ; Bader GD; Hao Z; Kornblau SM; Raught B; Schimmer AD
    Cancer Cell; 2015 Jun; 27(6):864-76. PubMed ID: 26058080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
    Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the structure-activity relationship and antileukemic activity of diacylpyramide compounds as human ClpP agonists.
    Zhang R; Wang P; Wei B; Chen L; Song X; Pan Y; Li J; Gan J; Zhang T; Yang CG
    Eur J Med Chem; 2023 Oct; 258():115577. PubMed ID: 37352796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.
    Ishizawa J; Zarabi SF; Davis RE; Halgas O; Nii T; Jitkova Y; Zhao R; St-Germain J; Heese LE; Egan G; Ruvolo VR; Barghout SH; Nishida Y; Hurren R; Ma W; Gronda M; Link T; Wong K; Mabanglo M; Kojima K; Borthakur G; MacLean N; Ma MCJ; Leber AB; Minden MD; Houry W; Kantarjian H; Stogniew M; Raught B; Pai EF; Schimmer AD; Andreeff M
    Cancer Cell; 2019 May; 35(5):721-737.e9. PubMed ID: 31056398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.
    Tan SF; Pearson JM; Feith DJ; Loughran TP
    Expert Opin Ther Targets; 2017 Jun; 21(6):583-590. PubMed ID: 28434262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutic agents in acute myeloid leukemia.
    Stone RM
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):163-6. PubMed ID: 17379102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mechanism of caseinolytic protease (ClpP) inhibition.
    Gersch M; Gut F; Korotkov VS; Lehmann J; Böttcher T; Rusch M; Hedberg C; Waldmann H; Klebe G; Sieber SA
    Angew Chem Int Ed Engl; 2013 Mar; 52(10):3009-14. PubMed ID: 23361916
    [No Abstract]   [Full Text] [Related]  

  • 9. Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches.
    Fernandes Â; Azevedo MM; Pereira O; Sampaio-Marques B; Paiva A; Correia-Neves M; Castro I; Ludovico P
    Oncotarget; 2015 Oct; 6(31):31428-40. PubMed ID: 25537507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KDM6 and KDM4 histone lysine demethylases emerge as molecular therapeutic targets in human acute myeloid leukemia.
    Boila LD; Chatterjee SS; Banerjee D; Sengupta A
    Exp Hematol; 2018 Feb; 58():44-51.e7. PubMed ID: 29111428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting mitochondrial RNA polymerase in acute myeloid leukemia.
    Bralha FN; Liyanage SU; Hurren R; Wang X; Son MH; Fung TA; Chingcuanco FB; Tung AY; Andreazza AC; Psarianos P; Schimmer AD; Salmena L; Laposa RR
    Oncotarget; 2015 Nov; 6(35):37216-28. PubMed ID: 26484416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
    Trus MR; Yang L; Suarez Saiz F; Bordeleau L; Jurisica I; Minden MD
    Leukemia; 2005 Jul; 19(7):1161-8. PubMed ID: 15902297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the downstream portion of the mitochondrial pathway of caspase activation in patients with acute myeloid leukemia.
    Gronda M; Brandwein J; Minden MD; Pond GR; Schuh AC; Wells RA; Messner H; Chun K; Schimmer AD
    Apoptosis; 2005 Dec; 10(6):1285-94. PubMed ID: 16215669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
    Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
    Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
    Birendra KC; DiNardo CD
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
    Milella M; Kornblau SM; Estrov Z; Carter BZ; Lapillonne H; Harris D; Konopleva M; Zhao S; Estey E; Andreeff M
    J Clin Invest; 2001 Sep; 108(6):851-9. PubMed ID: 11560954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.
    Cook GJ; Caudell DL; Elford HL; Pardee TS
    PLoS One; 2014; 9(11):e112619. PubMed ID: 25402485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.
    Voutsadakis IA
    Med Oncol; 2003; 20(4):311-24. PubMed ID: 14716027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia.
    Salerno L; Romeo G; Modica MN; Amata E; Sorrenti V; Barbagallo I; Pittalà V
    Eur J Med Chem; 2017 Dec; 142():163-178. PubMed ID: 28756878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.